Loading…
Outcomes of the Use of Direct-Acting Antiviral Therapy in Patients of Chronic Hepatitis-C of Genotype 3a
Objective: To measure the outcomes of direct acting Antiviral therapy in terms of frequency of Hepatocellular carcinoma after its use of in HCV patients infected with 3a genotype and to analyze the efficacy of double and triple regimen in HCV patients of Child Pugh’s class A and B respectively. Stud...
Saved in:
| Published in: | Pakistan Armed Forces medical journal 2023-08, Vol.73 (SUPPL-1), p.S69-72 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 72 |
| container_issue | SUPPL-1 |
| container_start_page | S69 |
| container_title | Pakistan Armed Forces medical journal |
| container_volume | 73 |
| creator | Zahoor, Sarmad Sikander Abdullah Muhammad Ahmed Saifullah Saroosh Zahoor Khan Amer Ali, Shoaib |
| description | Objective: To measure the outcomes of direct acting Antiviral therapy in terms of frequency of Hepatocellular carcinoma after its use of in HCV patients infected with 3a genotype and to analyze the efficacy of double and triple regimen in HCV patients of Child Pugh’s class A and B respectively.
Study Design: Quasi- experimental study.
Place and Duration of Study: Mayo Hospital, Lahore Pakistan, from May to Dec 2019.
Methodology: After applying inclusion and exclusion criteria 262 patients of 3a genotype were awarded as Child Pugh’s Class A and B and were treated with double and triple regimen for 12 and 24 weeks respectively. They were followed up with Ultrasound Abdomen every month and PCR Quantitative was done for evaluating Sustained Virological Response after 3 months of completing treatment.
Results: Out of 262 patients, 141(53.8%) were male and 121(46.2%) were female. 243(92.7%) patients achieved Sustained Virological Response. 9(3.4%) developed Hepatocellular carcinoma of which 8 were on triple regimen and 1 on double regimen.
Conclusion: direct Acting Antivirals are effective in achieving Sustained Virological Response but pose a greater risk for Hepatocellular carcinoma. So, they should be used with caution and serial monitoring. |
| doi_str_mv | 10.51253/pafmj.v73iSUPPL-1.5798 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2872169350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A767567248</galeid><sourcerecordid>A767567248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c213t-1b884bf5ffce84793f4361bcd46e6b1c8c79ae13364a62f40e21cb0e80671bc53</originalsourceid><addsrcrecordid>eNptkd1qGzEQhUVpoSbNM1TQ63X1L-2lcdukYIih8bXQKqNYxittJTngt-_aKS2FzlyMOJwzGvgQ-kjJUlIm-efJhfGwfNE8_thtt5uOLqXuzRu0YILSzhjB3qIFIZx0vRLmPbqt9UDmkpwJIhdo_3BqPo9QcQ647QHvKlyeX2IB37qVbzE941Vq8SUWd8SPeyhuOuOY8Na1CKldk-t9ySl6fA_TrLZYu_VFvoOU23kCzN0H9C64Y4Xb3_MG7b59fVzfd5uHu-_r1abzjPLW0WG-eQgyBA9G6J4HwRUd_JNQoAbqjde9A8q5Ek6xIAgw6gcChig92yS_QZ9e904l_zxBbfaQTyXNX1pmNKOq55L8dT27I9iYQm7F-TFWb1daaak0E2Z2Lf_jmvsJxuhzghBn_Z-Afg34kmstEOxU4ujK2VJir8DsFZj9A8xSewHGfwElZ4pX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2872169350</pqid></control><display><type>article</type><title>Outcomes of the Use of Direct-Acting Antiviral Therapy in Patients of Chronic Hepatitis-C of Genotype 3a</title><source>Nexis UK</source><source>ProQuest - Publicly Available Content Database</source><creator>Zahoor, Sarmad ; Sikander Abdullah ; Muhammad Ahmed Saifullah ; Saroosh Zahoor ; Khan Amer ; Ali, Shoaib</creator><creatorcontrib>Zahoor, Sarmad ; Sikander Abdullah ; Muhammad Ahmed Saifullah ; Saroosh Zahoor ; Khan Amer ; Ali, Shoaib</creatorcontrib><description>Objective: To measure the outcomes of direct acting Antiviral therapy in terms of frequency of Hepatocellular carcinoma after its use of in HCV patients infected with 3a genotype and to analyze the efficacy of double and triple regimen in HCV patients of Child Pugh’s class A and B respectively.
Study Design: Quasi- experimental study.
Place and Duration of Study: Mayo Hospital, Lahore Pakistan, from May to Dec 2019.
Methodology: After applying inclusion and exclusion criteria 262 patients of 3a genotype were awarded as Child Pugh’s Class A and B and were treated with double and triple regimen for 12 and 24 weeks respectively. They were followed up with Ultrasound Abdomen every month and PCR Quantitative was done for evaluating Sustained Virological Response after 3 months of completing treatment.
Results: Out of 262 patients, 141(53.8%) were male and 121(46.2%) were female. 243(92.7%) patients achieved Sustained Virological Response. 9(3.4%) developed Hepatocellular carcinoma of which 8 were on triple regimen and 1 on double regimen.
Conclusion: direct Acting Antivirals are effective in achieving Sustained Virological Response but pose a greater risk for Hepatocellular carcinoma. So, they should be used with caution and serial monitoring.</description><identifier>ISSN: 0030-9648</identifier><identifier>EISSN: 2411-8842</identifier><identifier>DOI: 10.51253/pafmj.v73iSUPPL-1.5798</identifier><language>eng</language><publisher>Rawalpindi: Knowledge Bylanes</publisher><subject>Abdomen ; Antiviral agents ; Antiviral drugs ; Blood transfusions ; Care and treatment ; Frequency distribution ; Gender ; Genetic aspects ; Genotype & phenotype ; Health surveillance ; Hepatitis B ; Hepatitis C ; Hepatitis C virus ; Interferon ; Liver ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Mortality ; Patient outcomes ; Patients ; Ultrasonic imaging ; Variables</subject><ispartof>Pakistan Armed Forces medical journal, 2023-08, Vol.73 (SUPPL-1), p.S69-72</ispartof><rights>COPYRIGHT 2023 Knowledge Bylanes</rights><rights>(c)2023 Pakistan Armed Forces Medical Journal</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2872169350/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2872169350?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25751,27922,27923,37010,44588,74896</link.rule.ids></links><search><creatorcontrib>Zahoor, Sarmad</creatorcontrib><creatorcontrib>Sikander Abdullah</creatorcontrib><creatorcontrib>Muhammad Ahmed Saifullah</creatorcontrib><creatorcontrib>Saroosh Zahoor</creatorcontrib><creatorcontrib>Khan Amer</creatorcontrib><creatorcontrib>Ali, Shoaib</creatorcontrib><title>Outcomes of the Use of Direct-Acting Antiviral Therapy in Patients of Chronic Hepatitis-C of Genotype 3a</title><title>Pakistan Armed Forces medical journal</title><description>Objective: To measure the outcomes of direct acting Antiviral therapy in terms of frequency of Hepatocellular carcinoma after its use of in HCV patients infected with 3a genotype and to analyze the efficacy of double and triple regimen in HCV patients of Child Pugh’s class A and B respectively.
Study Design: Quasi- experimental study.
Place and Duration of Study: Mayo Hospital, Lahore Pakistan, from May to Dec 2019.
Methodology: After applying inclusion and exclusion criteria 262 patients of 3a genotype were awarded as Child Pugh’s Class A and B and were treated with double and triple regimen for 12 and 24 weeks respectively. They were followed up with Ultrasound Abdomen every month and PCR Quantitative was done for evaluating Sustained Virological Response after 3 months of completing treatment.
Results: Out of 262 patients, 141(53.8%) were male and 121(46.2%) were female. 243(92.7%) patients achieved Sustained Virological Response. 9(3.4%) developed Hepatocellular carcinoma of which 8 were on triple regimen and 1 on double regimen.
Conclusion: direct Acting Antivirals are effective in achieving Sustained Virological Response but pose a greater risk for Hepatocellular carcinoma. So, they should be used with caution and serial monitoring.</description><subject>Abdomen</subject><subject>Antiviral agents</subject><subject>Antiviral drugs</subject><subject>Blood transfusions</subject><subject>Care and treatment</subject><subject>Frequency distribution</subject><subject>Gender</subject><subject>Genetic aspects</subject><subject>Genotype & phenotype</subject><subject>Health surveillance</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Interferon</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Ultrasonic imaging</subject><subject>Variables</subject><issn>0030-9648</issn><issn>2411-8842</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkd1qGzEQhUVpoSbNM1TQ63X1L-2lcdukYIih8bXQKqNYxittJTngt-_aKS2FzlyMOJwzGvgQ-kjJUlIm-efJhfGwfNE8_thtt5uOLqXuzRu0YILSzhjB3qIFIZx0vRLmPbqt9UDmkpwJIhdo_3BqPo9QcQ647QHvKlyeX2IB37qVbzE941Vq8SUWd8SPeyhuOuOY8Na1CKldk-t9ySl6fA_TrLZYu_VFvoOU23kCzN0H9C64Y4Xb3_MG7b59fVzfd5uHu-_r1abzjPLW0WG-eQgyBA9G6J4HwRUd_JNQoAbqjde9A8q5Ek6xIAgw6gcChig92yS_QZ9e904l_zxBbfaQTyXNX1pmNKOq55L8dT27I9iYQm7F-TFWb1daaak0E2Z2Lf_jmvsJxuhzghBn_Z-Afg34kmstEOxU4ujK2VJir8DsFZj9A8xSewHGfwElZ4pX</recordid><startdate>20230831</startdate><enddate>20230831</enddate><creator>Zahoor, Sarmad</creator><creator>Sikander Abdullah</creator><creator>Muhammad Ahmed Saifullah</creator><creator>Saroosh Zahoor</creator><creator>Khan Amer</creator><creator>Ali, Shoaib</creator><general>Knowledge Bylanes</general><general>AsiaNet Pakistan (Pvt) Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20230831</creationdate><title>Outcomes of the Use of Direct-Acting Antiviral Therapy in Patients of Chronic Hepatitis-C of Genotype 3a</title><author>Zahoor, Sarmad ; Sikander Abdullah ; Muhammad Ahmed Saifullah ; Saroosh Zahoor ; Khan Amer ; Ali, Shoaib</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c213t-1b884bf5ffce84793f4361bcd46e6b1c8c79ae13364a62f40e21cb0e80671bc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdomen</topic><topic>Antiviral agents</topic><topic>Antiviral drugs</topic><topic>Blood transfusions</topic><topic>Care and treatment</topic><topic>Frequency distribution</topic><topic>Gender</topic><topic>Genetic aspects</topic><topic>Genotype & phenotype</topic><topic>Health surveillance</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Interferon</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Ultrasonic imaging</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zahoor, Sarmad</creatorcontrib><creatorcontrib>Sikander Abdullah</creatorcontrib><creatorcontrib>Muhammad Ahmed Saifullah</creatorcontrib><creatorcontrib>Saroosh Zahoor</creatorcontrib><creatorcontrib>Khan Amer</creatorcontrib><creatorcontrib>Ali, Shoaib</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>PHMC-Proquest健康医学期刊库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Pakistan Armed Forces medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zahoor, Sarmad</au><au>Sikander Abdullah</au><au>Muhammad Ahmed Saifullah</au><au>Saroosh Zahoor</au><au>Khan Amer</au><au>Ali, Shoaib</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes of the Use of Direct-Acting Antiviral Therapy in Patients of Chronic Hepatitis-C of Genotype 3a</atitle><jtitle>Pakistan Armed Forces medical journal</jtitle><date>2023-08-31</date><risdate>2023</risdate><volume>73</volume><issue>SUPPL-1</issue><spage>S69</spage><epage>72</epage><pages>S69-72</pages><issn>0030-9648</issn><eissn>2411-8842</eissn><abstract>Objective: To measure the outcomes of direct acting Antiviral therapy in terms of frequency of Hepatocellular carcinoma after its use of in HCV patients infected with 3a genotype and to analyze the efficacy of double and triple regimen in HCV patients of Child Pugh’s class A and B respectively.
Study Design: Quasi- experimental study.
Place and Duration of Study: Mayo Hospital, Lahore Pakistan, from May to Dec 2019.
Methodology: After applying inclusion and exclusion criteria 262 patients of 3a genotype were awarded as Child Pugh’s Class A and B and were treated with double and triple regimen for 12 and 24 weeks respectively. They were followed up with Ultrasound Abdomen every month and PCR Quantitative was done for evaluating Sustained Virological Response after 3 months of completing treatment.
Results: Out of 262 patients, 141(53.8%) were male and 121(46.2%) were female. 243(92.7%) patients achieved Sustained Virological Response. 9(3.4%) developed Hepatocellular carcinoma of which 8 were on triple regimen and 1 on double regimen.
Conclusion: direct Acting Antivirals are effective in achieving Sustained Virological Response but pose a greater risk for Hepatocellular carcinoma. So, they should be used with caution and serial monitoring.</abstract><cop>Rawalpindi</cop><pub>Knowledge Bylanes</pub><doi>10.51253/pafmj.v73iSUPPL-1.5798</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-9648 |
| ispartof | Pakistan Armed Forces medical journal, 2023-08, Vol.73 (SUPPL-1), p.S69-72 |
| issn | 0030-9648 2411-8842 |
| language | eng |
| recordid | cdi_proquest_journals_2872169350 |
| source | Nexis UK; ProQuest - Publicly Available Content Database |
| subjects | Abdomen Antiviral agents Antiviral drugs Blood transfusions Care and treatment Frequency distribution Gender Genetic aspects Genotype & phenotype Health surveillance Hepatitis B Hepatitis C Hepatitis C virus Interferon Liver Liver cancer Liver cirrhosis Liver diseases Mortality Patient outcomes Patients Ultrasonic imaging Variables |
| title | Outcomes of the Use of Direct-Acting Antiviral Therapy in Patients of Chronic Hepatitis-C of Genotype 3a |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A35%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20of%20the%20Use%20of%20Direct-Acting%20Antiviral%20Therapy%20in%20Patients%20of%20Chronic%20Hepatitis-C%20of%20Genotype%203a&rft.jtitle=Pakistan%20Armed%20Forces%20medical%20journal&rft.au=Zahoor,%20Sarmad&rft.date=2023-08-31&rft.volume=73&rft.issue=SUPPL-1&rft.spage=S69&rft.epage=72&rft.pages=S69-72&rft.issn=0030-9648&rft.eissn=2411-8842&rft_id=info:doi/10.51253/pafmj.v73iSUPPL-1.5798&rft_dat=%3Cgale_proqu%3EA767567248%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c213t-1b884bf5ffce84793f4361bcd46e6b1c8c79ae13364a62f40e21cb0e80671bc53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2872169350&rft_id=info:pmid/&rft_galeid=A767567248&rfr_iscdi=true |